Article
Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Neuro-oncology - 26 Nov 2020
Schell Marianne, Pflüger Irada, Brugnara Gianluca, Isensee Fabian, Neuberger Ulf, Foltyn Martha, Kessler Tobias, Sahm Felix, Wick Antje, Nowosielski Martha, Heiland Sabine, Weller Michael, Platten Michael, Maier-Hein Klaus H, Von Deimling Andreas, Van Den Bent Martin J, Gorlia Thierry, Wick Wolfgang, Bendszus Martin, Kickingereder Philipp
Abstract excerpt
BACKGROUND: This study validated a previously described diffusion MRI phenotype as a potential predictive imaging biomarker in patients with recurrent glioblastoma receiving bevacizumab (BEV). METHODS: A total of 396/596 patients (66%) from the prospective randomized phase II/III EORTC-26101 trial (with n = 242 in the BEV and n = 154 in the non-BEV arm) met the inclusion criteria with availability of anatomical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.